An experimental drug that targets three metabolic pathways has shown promising results in people with type 2 diabetes. An experimental drug that targets three metabolic pathways has produced substantial improvements in blood sugar control and weight loss in people with type 2 diabetes. In a phase 3 clinical trial published in The Lancet, participants receiving […]This is a curated summary.